Furthermore, CIP2A auto-antibodies were present more frequently (29% vs. 16%) in the sera of prostate cancer patients with a high Gleason score (seven or higher) when compared to patients with less aggressive disease [6]. This evidence concerns the gene CIP2A and prostate carcinoma.